High-Load Core@Shell Nanocarriers with Irinotecan and 5-Fluorouracil for Combination Chemotherapy in Colorectal Cancer

被引:0
作者
Notter, Silke [1 ]
Choezom, Dolma [2 ,3 ,4 ]
Griebel, Titus [2 ,3 ]
Ramos-Gomes, Fernanda [3 ]
Moebius, Wiebke [3 ]
De Oliveira, Tiago [4 ]
Conradi, Lena-Christin [4 ]
Alves, Frauke [2 ,3 ,5 ]
Feldmann, Claus [1 ]
机构
[1] Karlsruhe Inst Technol KIT, Inst Inorgan Chem, Engesserstr 15, D-76131 Karlsruhe, Germany
[2] Univ Med Ctr Goettingen UMG, Clin Haematol & Med Oncol, Robert Koch Str 40, D-37075 Gottingen, Germany
[3] Max Planck Inst Multidisciplinary Sci MPI NAT, Dept Neurogenet, City Campus,Hermann Rein Str 3, D-37075 Gottingen, Germany
[4] Univ Med Ctr Goettingen UMG, Dept Gen Visceral & Pediat Surg, Robert Koch Str 40, D-37075 Gottingen, Germany
[5] Univ Med Ctr Goettingen UMG, Inst Diagnost & Intervent Radiol, Robert Koch Str 40, D-37075 Gottingen, Germany
来源
SMALL SCIENCE | 2024年 / 4卷 / 11期
关键词
5-fluorouracil; colorectal cancer; drug delivery; irinotecan; tumor combination therapy; DRUG-DELIVERY; NANOPARTICLES; PACLITAXEL; PROGRESS; TRIAL;
D O I
10.1002/smsc.202400196
中图分类号
TB3 [工程材料学];
学科分类号
0805 ; 080502 ;
摘要
Colorectal cancer (CRC) is the third most common cancer type and second leading cause of cancer-related deaths worldwide, requiring novel drug-delivery concepts. ITC@ZrO(TocP)/ZrO(FdUMP) core@shell nanocarriers (designated ITC-FdUMP-NC) with the clinically relevant chemotherapeutics irinotecan (ITC) and fluoro-2 '-deoxyuridine-5 '-phosphate (FdUMP) (active derivative of 5 '-fluorouracil/5-FU) are a new type of nanocarrier with high drug payload (22 wt% of lipophilic ITC: particle core; 10 wt% of hydrophilic FdUMP: particle shell). The nanocarriers are tested in different CRC cell lines, a normal cell line, and rectal cancer patient-derived organoids (PDOs). Fluorescence-labeled nanocarriers show efficient uptake by all CRC cells and allow to distinctly track the intracellular trafficking toward endolysosomal compartments. Although free chemotherapeutic drugs exhibit a greater potency in 2D cell cultures, ITC-FdUMP-NC demonstrate equivalent cytotoxic efficacies as the freely dissolved drugs in the more complex 3D rectal cancer PDOs. The sustained drug-release profile of the nanocarriers contrasts favorably with conventional free drugs, potentially enhancing the therapeutic outcome in vivo. With a chemotherapeutic cocktail comparable to the clinically applied FOLFIRI (ITC + 5-FU), the ITC-FdUMP-NC represent a novel type of nanocarrier with high anti-tumor effect and high drug payload, offering a promising strategy to circumvent chemoresistance and to improve therapy efficacy in vivo with less side effects. A clinically relevant drug cocktail of irinotecan (ITC) and 5-fluorouridine (5-FU) is combined in a single nanocarrier with high drug payload (32%). The nanocarriers show efficient uptake and high efficacy in different human colon cancer and human rectal cancer cell lines as well as rectal cancer patient-derived organoids, also allowing to elucidate the membrane-trafficking pathway.image (c) 2024 WILEY-VCH GmbH
引用
收藏
页数:14
相关论文
共 50 条
  • [41] Phase II study of irinotecan, leucovorin, 5-fluorouracil and tegafur/uracil for metastatic colorectal cancer
    Kono, T
    Ebisawa, Y
    Tomita, I
    Chisato, N
    Kamiya, K
    Asama, T
    Ayabe, T
    Ashida, T
    Kohgo, Y
    Kasai, S
    [J]. JOURNAL OF CHEMOTHERAPY, 2005, 17 (02) : 224 - 227
  • [42] Phase I/II study of irinotecan, 5-fluorouracil, and I-leucovorin combination therapy (modified Saltz regimen) in patients with metastatic colorectal cancer
    Goto A.
    Yamada Y.
    Hosokawa A.
    Ura T.
    Arai T.
    Hamaguchi T.
    Muro K.
    Shimada Y.
    Shirao K.
    [J]. International Journal of Clinical Oncology, 2004, 9 (5) : 364 - 368
  • [43] Preclinical Synergistic Combination Therapy of Lurbinectedin with Irinotecan and 5-Fluorouracil in Pancreatic Cancer
    Tummala, Tej
    Uruchurtu, Ashley Sanchez Sevilla
    Cruz, Arielle De La
    Huntington, Kelsey E.
    George, Andrew
    Liguori, Nicholas R.
    Zhang, Leiqing
    Zhou, Lanlan
    Abbas, Abbas E.
    Azzoli, Christopher G.
    El-Deiry, Wafik S.
    [J]. CURRENT ONCOLOGY, 2023, 30 (11) : 9611 - 9626
  • [44] Synergistic antitumor effect of 5-fluorouracil in combination with parthenolide in human colorectal cancer
    Kim, Se-Lim
    Kim, Seong Hun
    Kieu Thi Thu Trang
    Kim, In Hee
    Lee, Seung-Ok
    Lee, Soo Teik
    Kim, Dae Ghon
    Kang, Sang-Beom
    Kim, Sang-Wook
    [J]. CANCER LETTERS, 2013, 335 (02) : 479 - 486
  • [45] Diosmetin Exerts Synergistic Effects in Combination with 5-Fluorouracil in Colorectal Cancer Cells
    Kamran, Sareh
    Sinniah, Ajantha
    Chik, Zamri
    Alshawsh, Mohammed Abdullah
    [J]. BIOMEDICINES, 2022, 10 (03)
  • [46] Folic acid-targeted β-lactoglobulin nanocarriers for enhanced delivery of 5-fluorouracil and sodium butyrate in colorectal cancer treatment
    Heydarian, Ronak
    Divsalar, Adeleh
    Kouchesfehani, Homa Mohseni
    Rasouli, Milad
    [J]. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2025, 671
  • [47] Final analysis of colorectal cancer patients treated with irinotecan and 5-fluorouracil plus folinic acid neoadjuvant chemotherapy for unresectable liver metastases
    Barone, C.
    Nuzzo, G.
    Cassano, A.
    Basso, M.
    Schinzari, G.
    Giuliante, F.
    D'Argento, E.
    Trigila, N.
    Astone, A.
    Pozzo, C.
    [J]. BRITISH JOURNAL OF CANCER, 2007, 97 (08) : 1035 - 1039
  • [48] Final analysis of colorectal cancer patients treated with irinotecan and 5-fluorouracil plus folinic acid neoadjuvant chemotherapy for unresectable liver metastases
    C Barone
    G Nuzzo
    A Cassano
    M Basso
    G Schinzari
    F Giuliante
    E D'Argento
    N Trigila
    A Astone
    C Pozzo
    [J]. British Journal of Cancer, 2007, 97 : 1035 - 1039
  • [49] Phase I/II trial of irinotecan plus high-dose 5-fluorouracil (TTD regimen) as first-line chemotherapy in advanced colorectal cancer
    Aranda, E
    Carrato, A
    Cervantes, A
    Sastre, J
    Gómez, MA
    Abad, A
    Masutti, B
    Ribera, F
    Marcuello, E
    Pronk, L
    Balcells, M
    Díaz-Rubio, E
    [J]. ANNALS OF ONCOLOGY, 2004, 15 (04) : 559 - 567
  • [50] Modified irinotecan plus bolus 5-fluorouracil/L-leucovorin for metastatic colorectal cancer at a single institution in Japan
    Suenaga, Mitsukuni
    Mizunuma, Nobuyuki
    Shouji, Daigo
    Shinozaki, Eiji
    Matsusaka, Satoshi
    Chin, Keisho
    Oya, Masatoshi
    Yamaguchi, Toshiharu
    Muto, Tetsuichiro
    Hatake, Kiyohiko
    [J]. JOURNAL OF GASTROENTEROLOGY, 2008, 43 (11) : 842 - 848